Objective: The purpose of this study was to examine the outcomes of a vascular hybrid polytetrafluoroethylene (PTFE) graft, provided with a nitinol-reinforced section (NRS) on one end, in hemodialysis vascular access placement.
The life expectancy of hemodialysis-dependent patients has been increasing in the last few decades. 1 Autogenous arteriovenous fistula (AVF) is the "gold standard" for hemodialysis access for its good longterm patency. 2, 3 After repeated failure of an AVF and exhaustion of venous material, the use of a prosthetic arteriovenous graft (AVG) is the best alternative. Many types of prostheses have been used so far, with 1-year patency rates generally lower than for AVF. A review including 34 studies reported a cumulative 18-month primary patency of 51% for AVF and 33% for AVG. 4 Intimal hyperplasia (IH) is considered to be the main cause of graft occlusion. 1 The increasing need for long-lasting vascular accesses has fostered the research on IH. The turbulent flow, strictly related to the width of the anastomosis angle, produces shear stress on the vein wall. 5 The subsequent endothelial injury promotes smooth muscle cell migration and proliferation and eventually is responsible for platelet recruitment and coagulation cascade activation. [6] [7] [8] [9] [10] The next step is graft thrombosis. In light of these findings, a new concept of vascular hybrid prosthesis has been developed, whereby the vein-side anastomosis is replaced by a nitinol-reinforced section (NRS), to be inserted and deployed into the target vein, to form an end-to-end junction. This design, based on a straight geometry, is intended to keep the flow laminar, reducing shear stress and thus preventing IH. 11 Nonetheless, it is still unclear whether the straight geometry actually allows laminar flow in AVGs. Evidence that a nitinol stent at the venous end of a standard polytetrafluoroethylene (PTFE) graft improved patency of a failing AVG compared with simple angioplasty supports the validity of the hybrid concept. 12 The idea of replacing the distal anastomosis of a graft by a nitinol-covered stent was also described by Lachat et al. 13 The aim of the study was to report a 2-year experience with the hybrid graft in hemodialysis access and to analyze outcomes and complications.
METHODS
Patient cohort. A multicenter retrospective cohort study was conducted including all consecutive patients who underwent implantation of the Gore Hybrid Vascular Graft (GHVG; W. L. Gore & Associates, Flagstaff, Ariz) for hemodialysis access between October 2013 and November 2015 at the University Hospital Gaetano Martino, Messina, Italy, and at Noto-Pasqualino Clinic, Palermo, Italy. A propensity-matched control group was obtained from consecutive patients who underwent standard PTFE AVG implantation between January 2010 and July 2013 at the same centers. Patient demographics and clinical and procedure data were collected in a dedicated prospectively maintained Excel (Microsoft, Redmond, Wash) database. This study is in agreement with the principles outlined in the Declaration of Helsinki. The protocol and the informed consent were approved by the Institutional Review Board. All patients gave a written informed consent to participate in a study. This study did not undergo editorial review, nor was it supported by representatives of the graft manufacturer.
Preoperative protocol. All patients underwent preoperative routine blood tests and careful physical examination, evaluating the presence and validity of distal pulses, skin inflammation, and any evidence of central venous obstruction, such as edema and collateral veins of the upper extremity or chest wall. Allen test was routinely performed. Duplex ultrasound (Vivid 4; GE Healthcare, Chalfont St Giles, United Kingdom) arterial and venous preoperative mapping was routinely performed. Target artery and vein diameters were measured on the transverse ultrasound scan, with the patient supine at room temperature, by experienced operators. Vein compressibility, distensibility, thickness, and continuity were assessed with a rubber tourniquet in place. Arterial patency and presence of triphasic flow were ascertained by duplex ultrasound with a 7 MHz linear probe at 60-degree insonation angle. Patients were deemed unsuitable for autogenous access placement if a superficial vein, including the upper arm cephalic and basilic vein, at least 2.5 mm in diameter was lacking or was present for a short track before the confluence into the deep veins, in both the dominant and nondominant arms. 14 16 It consists of a PTFE graft with an NRS at one end. The continuous luminal surface provides additional resistance to thrombosis and seroma formation thanks to covalently bonded heparin of porcine origin and a low permeability film. The NRS is conceived to be inserted directly through a venotomy or over the wire through a peel-away sheath into the target vessel, to be deployed so as to replace the venous anastomosis with an end-to-end junction. The deployment is carried out by pulling a constraining wire. The endoluminal position of the proximal end of the NRS is defined as the landing zone. The idea behind this design is to reduce turbulent flow to prevent IH and, at the same time, to allow the treatment of stenoses of the target vein. 11 The NRS is available in five diameters (5-9 mm) and two lengths (5 and 10 cm). The nonreinforced end is anastomosed to the inflow artery with a running suture like a standard AVG. It has standard 6-mm diameter and is tapered to adapt to the size of the NRS. It uses stretch technology and should be put under tension before placement of the suture.
Technique. Four surgeons performed the procedures. All procedures were carried out in a surgical room equipped with a mobile fluoroscopic C-arm (Philips BV Pulsera; Philips Medical Systems, Amsterdam, The Netherlands) because contrast angiography is required. Vascular accesses were placed in both the upper and lower limbs. The selection of graft size and access configuration was made by the surgeon. 17 Because the graft by design occludes the distal venous outflow, the NRS was placed as distal as reasonable, based on vein diameter, aiming to safeguard the chance for future access placements and preserving the confluence of venous branches whenever possible. Optimal NRS oversize was considered to be 5% to 20%, as suggested in the instructions for use. The technique of brachial-axillary graft implantation involved the surgical incision in the armpit with dissection of the axillary vessels. The brachial artery was then exposed through an incision proximal to the elbow. The nonstented part of the device was stretched and tunneled in the subcutaneous tissue. The NRS was inserted into the axillary vein through a venotomy or a peel-away sheath. The NRS was then advanced inside the vein except for about 2 cm, deployed, and secured to the vein with two 6-0 polypropylene stitches (Fig 1, A) . These sutures, required per instructions for use, prevent graft dislocation during the procedure. The arterial anastomosis was performed in an end-to-side fashion, as for traditional grafts. As a final step, a balloon dilation of the stent was performed through direct puncture of the prosthesis. Any additional endovascular procedure addressing outflow stenoses was performed at this time. Alternatively, if doubt persisted about graft sizing, angiography was performed before the selection of the GHVG. Completion control was routinely performed at the end of the procedure by contrast angiography when it was not contraindicated (Fig 1, B) .
Patients not yet under hemodialysis were controlled with duplex ultrasound only. For the brachialantecubital forearm loop, the brachial artery and the antecubital vein were exposed through a single surgical incision. The prosthesis was then tunneled in a loop configuration. A comparable approach has been used for femoral-femoral looped inguinal access placement. Through an inguinal incision, the femoral vessels were exposed, and the superficial femoral vein served as target vein (Fig 2) . For axilloaxillary loop AVG, the axillary vessels were exposed through an axillary incision. All procedures were performed under local anesthesia (mepivacaine hydrochloride 2%), locoregional plexus block, or spinal anesthesia, except axilloaxillary loop AVG, which was performed under general anesthesia. Antibiotic prophylaxis with cephalosporin was performed before the surgical incision.
Postoperative management. Patients were discharged with antiplatelet therapy (clopidogrel, 75 mg/d). Required recovery time before cannulation was 2 to 4 weeks. The vascular access was evaluated with duplex ultrasound through hospital discharge, at 30 days, and every 3 months after the procedure. Flow measurements were performed monthly. When dynamic venous pressure >200 mm Hg with flow of 300 mL/min, Kt/V <0.8, or recirculation >25% was present, duplex ultrasound or angiographic control was performed. 18 Outcomes and statistical analysis. Interventions, complications, and outcomes were defined according to the reporting standards on arteriovenous accesses developed by the Society for Vascular Surgery and the American Association for Vascular Surgery. 19 Primary end points were survival, functional primary patency, assisted primary patency, and secondary patency. Secondary end points were vascular access-related complications: postoperative hematoma, limb edema, graft infection, anastomosis or venous stenosis, steal syndrome, and other complications. Continuous variables are reported as 
RESULTS
Patient population. Thirty-two patients received a GHVG for hemodialysis access placement. The historical control group included 43 patients. Demographics and baseline characteristics for both groups are shown in Table I . Among patients who received a GHVG, 28 patients (88%) were under hemodialysis treatment for end-stage renal disease, and in 4 patients (13%), the anticipated start of hemodialysis treatment was within 6 weeks. Four patients (13%) received the GHVG as a first choice because they lacked superficial veins >2.5 mm in diameter and long enough for an effective AVF to be placed. The remaining had at least one previous intervention of vascular access placement. The mean target vein diameter was 5.8 6 1.0 mm (range, 3.8-8.0 mm; median, 5.8 mm).
Treatment characteristics. The mean duration of interventions was 78 6 27 minutes (range, 40-155; median, 70). The mean amount of contrast agent used was 30 6 8 mL, (range, 20-54; median, 28). The mean NRS oversize was 20% 6 7% (range, 3.4%-34.6%; median, 19.7%). The NRS size of the implanted GHVG ranged from 5 to 9 mm in diameter, and both lengths were used (Table II) . The graft configuration was brachialaxillary, brachial-basilic loop, brachial-antecubital loop, axilloaxillary loop, and femoral-femoral loop in 22 cases (69%), 5 cases (16%), 3 cases (9%), 1 case (3%), and 1 case (3%), respectively. In six cases, additional planned endovascular procedures were carried out to treat stenoses of the outflow vein or central veins: three cases were treated with a covered stent in the right innominate vein, axillary vein, and brachial vein, respectively; three cases were treated with simple balloon angioplasty of the right innominate vein, axillary vein, and superficial femoral vein, respectively. Perioperative outcomes. Technical success was achieved in all 32 cases; 29 (91%) GHVGs have been successfully used for dialysis, whereas 3 (9%) have failed before starting cannulation. Mean time to cannulation was 20 6 6 days (range, 13-37; median, 20). Early complications (within 30 days) were as follows: surgical site hematoma in three cases (9%) of brachial-axillary configuration, none of which required surgical revision; limb edema in one patient (3%) due to a focal stenosis of superior vena cava that was addressed with a balloon-expandable bare-metal stent; acute lower limb ischemia in one patient (3%) with femoral-femoral configuration, successfully treated with thrombectomy; and graft infection in two cases (6%), treated with graft explantation and central venous catheter placement. Two patients (6%), both in poor general condition, died in the hospital. Follow-up. Three patients were lost to follow-up. The mean follow-up time was 15 6 11 months (range, 0-33 months; median, 15.5). During follow-up, two other patients died of unrelated causes. During follow-up, two outflow vein stenoses were detected and treated with covered stent implantation and simple balloon angioplasty, respectively. Six occlusions occurred and were treated with simple thrombectomy, except for three cases that required adjunctive endovascular procedures on the outflow vein (two stenting and one balloon angioplasty). One patient presented with graft infection at 7 months and underwent graft explantation. A histologic analysis revealed IH proximal to the end of the NRS. No steal syndrome was observed during follow-up. Mean access flow was 1202 6 436 mL/min (range, 650-2200; median, 1150). After PSM, two groups of 25 patients each were created with correction of the differences in demographics and baseline characteristics (Table III) . Twoyear survival estimates for hybrid and standard PTFE groups were 91% 6 6% and 82 6 9% (P > .05), respectively (Fig 3) . One-year functional primary, functional assisted primary, and functional secondary patency estimates for the hybrid group vs the standard PTFE group were 66% 6 10% vs 51% 6 10% (P > .05), 75% 6 9% vs 51% 6 10% (P > .05), and 79% 6 9% vs 67% 6 10% (P > .05; Figs 4 to 6). The probability of functional primary, assisted primary, and secondary patency during 24 months for the GHVG group was 40%, 50%, and 38% more than for the PTFE group. However, no statistical significance was reached (Table IV) . Secondary outcomes showed no statistically significant difference between the groups. The logistic regression model was statistically significant, c 2 (3) ¼ 10.984 (P < .001). The model explained 43.0% (Nagelkerke R 2 ) of the variance of GHVG-related reintervention and correctly classified 87.5% of cases. Of the three predictor variables (target vein diameter, previous vascular access surgery on the same limb, and diabetes), only one was statistically significant: target vein diameter. Reducing target vein diameter was associated with an increased likelihood of GHVG-related reintervention (Table V) .
DISCUSSION
AVF is currently the first choice in patients requiring access for hemodialysis treatment. An AVG is required when native vein anatomy is deemed disadvantaged or after repeated AVF failures. Reported 1-year primary and secondary patency rates for standard PTFE AVGs range from 40% to 60% and from 50% to 70%, respectively. [21] [22] [23] [24] In this study, we report on 32 patients treated with GHVG, with 1-year functional primary and secondary patency rates of 66% 6 10% and 79% 6 9%, respectively. Although the usefulness of the AVG is undeniable, its Achilles heel is the venous anastomosis. The main cause of failure of AVGs is considered to be stenosis at the venous anastomosis and subsequent thrombosis. This stenosis is mainly due to IH, which is triggered by turbulent flow, shear stress, and compliance mismatch between graft and vein. 10, 25 Turbulence is a well-established factor in the Fluid dynamics and geometry of the anastomosis have been addressed by several in vitro and in vivo models in an effort to understand and to prevent the development of IH. [28] [29] [30] The influence of the anastomotic angle on the flow was studied using a porcine model. 5 This consisted of an aortic graft interposition with end-to-side configuration. Distal anastomoses were performed with angles of 90, 45, or 15 degrees. The anastomoses of both 90 and 45 degrees showed a recirculation zone, whereas no turbulence of the flow was documented in the 15-degree ones. Hakaim et al 31 showed that a sharp anastomotic angle, along with the incorporation of a flow diffuser, increased patency in brachial-axillary AVGs compared with a control group matched for age and gender. The hallmark of GHVG is the absence of a sewn venous anastomosis, replaced by a 5-cm or 10-cm NRS. This feature, besides offering a technically easier surgical approach to the target vein, allows a straight venous anastomotic junction, which might theoretically reduce the amount of turbulent flow. Nonetheless, the finding of IH is not totally excluded, as attested to in the single histologic analysis available. More anatomic samples are necessary for any conclusion to be drawn in this regard. The duration of intervention is comparable to that of standard AVG implantation. Time spared by sutureless anastomosis offsets the additional angiographic time. Clopidogrel might account for our three hematomas. However, it was reported to reduce AVF thrombosis without increasing bleeding events. 32 Few reports on the use of GHVG are present in the literature to date. Anaya-Ayala et al 33 reported on a series of 25 patients who received GHVG for hemodialysis access, with 1-year primary and secondary patency of 66% 6 8% and 69% 6 7%, respectively. We observed a slightly higher secondary patency in our series. However, the selection criteria adopted by the two surgical groups are different. Indeed, Anaya-Ayala et al included only patients with a target vein <3 mm in diameter, whereas we excluded these patients and considered eligible only patients with a target vein at least 4 mm in diameter. Unlike Anaya-Ayala et al, we did not use the percutaneous approach, but we exposed the target vein in all cases. Moreover, our group implanted the graft in a wider variety of configurations compared with Anaya-Ayala et al, who reported exclusively brachial-axillary and axilloaxillary loop configurations. In our series, we observed five stenoses of the outflow vein, detected after AVG malfunction or occlusion. Most of the stenoses were located in the axillary or subclavian vein, next to a venous valve, and were mainly treated by positioning a Viabahn stent (W. L. Gore & Associates). The treatment of outflow vein stenoses with covered stents was previously described for standard AVGs, both as a planned procedure and during reintervention. [33] [34] [35] Since the availability of a graft with 10-cm NRS, we started to perform intraoperative angiography routinely before the selection of the graft. 11 Indeed, in our current practice, starting from the latest cases, the finding of a venous valve close to the expected landing zone of the NRS is a criterion to prefer the longer length. The 5-cm length, dominant in our series, was the only one used during the first period of our experience. As argued by Anaya-Ayala et al, the sutureless venous anastomosis may give rise to additional difficulties in case of reintervention. 33 In our experience, of six cases of thrombectomy, one case required landing zone balloon angioplasty and two cases required angioplasty and stenting as adjunctive procedures, as a venous stenosis was present proximal to the end of the graft. Actually, most thrombectomies failed to result in a satisfactory lengthening of hybrid access survival as reocclusion occurred within a few weeks in four cases. The reason for this unsatisfactory outcome was unclear, and we believe a deterioration of proximal outflow may have played a role. On the other hand, maintenance procedures, carried out for access malfunction with a patent graft, were successful and were not followed by further reinterventions or occlusion. For this reason, in our opinion, a strict compliance with the follow-up controls is critical for this type of graft. Our multivariate analysis provided an insight into possible strategies to improve outcomes. In effect, it has shown that a reduction of target vein diameter was associated with an increased likelihood of GHVGrelated reintervention. We acknowledge that this finding is limited because of the small size of the sample and needs to be confirmed with further studies. Nonetheless, in our opinion, additional caution is prompted in the selection of the target vein whenever the diameter is in the lower end of the recommended range. In these cases, a possible solution could be to achieve a more proximal and thus larger in diameter landing zone by selecting the 10-cm NRS.
This study presents some important limitations. The sample is heterogeneous in graft configurations, its size is limited, and the follow-up is relatively short. Larger cohorts of patients, a longer observation period, and possibly a multicenter randomized trial may help in defining the role for GHVG. A multicenter observational study, including a greater number of participating centers experienced with GHVG, is currently being conducted under the guidance of the first author. Whether the in-line graft-vein junction effectively produces laminar flow, in patients' anatomies, has not yet been proved. In silico and in vitro models could be designed to better understand the fluid dynamics of real-anatomy geometries.
CONCLUSIONS
The GHVG is a safe and effective alternative to standard PTFE AVG. Based on our results, a careful planning of the landing zone is advisable when the target vein is small because a decrease in vein diameter was associated with higher risk of reintervention. Larger studies and randomized trials are needed to better delineate the indications for GHVG. 
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